Go online to PeerView.com/WUP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in hemophilia explores the evidence supporting novel, emerging hemophilia therapeutics and provides guidance on the implications of the evidence presented for real-world practice. Upon completion of this accredited CE activity, participants should be better able to: Discuss current challenges and new developments in the management of patients with hemophilia A and B, Review the mechanism of action of RNA interference and the role of novel, investigational nonfactor replacement therapies in hemophilia A and B, Evaluate the safety and efficacy profiles and clinical trial data for emerging nonfactor, nongene therapies for treating patients with hemophilia A and B with or without inhibitors.